Next Phase Newsletter

A multinational pharmaceutical company headquartered in Japan is actively looking globally for opportunities to in-license cutting-edge, early stage therapeutic assets. Sponsored research may also be considered with a focus on Japan-based academic institutions. In addition, the firm is an active investor into Series A raises and invests up to $1M in initial investment, for which the firm considers global opportunities.

The firm’s external R&D is focused on both neurodegenerative and neurodevelopmental diseases including Parkinson’s disease, autism, Rett Syndrome, fragile X, and lysosomal storage diseases. The firm is interested in platform technology and early stage hits/seeds in CNS, orphan disease, and genetically defined platform and asset focused companies with strong emphasis on novel drug discovery platforms. This includes new MOAs such as gene therapy, stem cell therapy, BBB penetrating biologics and monoclonal antibodies acting on new targets. The firm is also interested in later-stage assets (phase III to on the market) in diabetes, immunology, and infectious diseases for the Asia markets.

The firm is looking for assets that would be strategic a fit with its current portfolio. The firm is willing to negotiate regional rights based each therapeutic field. For example, in immunology and neurology, the firm would prefer both US and Asia rights. In diabetes, infectious diseases, and other areas, the firm can request Asia rights only.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A hybrid family office and operating company with USA offices makes investments ranging from approximately $500,000 to $100 million into companies, and due to its funding structure has no requirements for holding period or capital structure. The firm makes investments in the forms of equity, controlling interest, in-licensing, MBO/LBO, growth capital and is also willing to co-invest. The firm is looking for companies located around the globe and makes around 5-15 investments in a given year.

The firm is looking for companies in sectors of Biotech Therapeutics and Diagnostics, Medtech, Digital Health, R&D Services, and Biotech Other. The firm is willing to consider all indications including orphan diseases, though they have some additional interest/experience is areas of Women’s Health, GI, Oncology and Cardiovascular, and Personalized Medicine including Proteomics and Genomics. The firm is most interested in companies that are in Phase II or later, nearing commercialization where the firm is capable of utilizing its operating company to scale up the company’s sales, marketing and distribution. That being said the firm has made earlier stage investments in the past and is open to considering highly innovative and compelling early stage companies. The firm is also interested in companies developing consumables/reagents, service providers, food and nutraceuticals.

The firm looks to work with management teams with experience and grit and generally looks to take a board seat although it is not a requirement. The firm looks to leverage the use of its operating company to assist the company’s sales marketing and distribution efforts as well as providing assistance in operations management.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm based in China is currently investing from their first USD fund and actively raising for their second USD fund to invest in companies based in USA and Canada. The firm also shifted their paradigm that in the next 5 years, they will have 60% of the fund and portfolio companies from the U.S. The firm focuses on Series A-B deals within the US, Canada, and China and typically invests USD 2-5 million per deal. The firm typically co-invests, but is willing to lead in specific situations.

The firm is opportunistic within the therapeutics and medical technology domains. However, for therapeutics, the firm focuses mostly on assets that are currently in Phase I or Phase II clinical trials. For Medical Devices, they prefer technologies that already have 510k or PMA clearance. Most importantly though, when investing, The firm requires that the technology has strong clinical evidence of efficacy. Strong evidence of efficacy is the most important criteria for the firm when investing in therapeutics and medical technology.

The firm is looking for a management team with a strong history of success as serial entrepreneurs or with strong clinical backgrounds. For investment opportunities without FDA clearance, the firm prefers seeing management teams with prior success in achieving FDA approval or candidates who have strong background from big pharma.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

An early-stage healthcare technology venture capital investment firm based in Boston raised $200 million for its first dedicated healthcare technology-focused fund. The firm primarily invests in companies in the seed, Series A and B stages targeting healthcare technology and services and is seeking 8-10 new investments within the next year. The firm typically invests an initial range of $1-8M and may go up to investing $20M per company overall, though the size may vary depending on the opportunity. The firm primarily invests in companies based in the US, though is open to companies on a global level. The firm seeks to be a significant investor in any of its portfolio companies and will often serve on the boards of those companies.

In the healthcare technology sector, the firm is actively seeking new investments in healthcare software and services sectors with a specific focus on healthcare analytics, healthcare infrastructure, and novel service delivery models. The firm has a specific interest in transformational technologies and services that enable value-based healthcare and leverage wireless, data and analytics technologies. The firm currently is not focused on therapeutics or medical device investment opportunities, though has interest in medical devices with a software/data component, such as sensors. The firm may be open to 510K devices, however, it is not interested in regulated devices. The firm is indication agnostic and invests in pre-revenue to growth stage products.

The firm seeks to invest in privately held companies with a strong and experience management team. The group prefers to invest in companies with cutting-edge technologies and large market potential.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A biotech sector investment firm headquartered in China opened a Boston office and raised a USD investment fund. The firm can allocate from $200,000 to $800,000 of equity capital in seed round companies and can make investments ranging from $1 to $10 million in series A companies. The firm looks to help its portfolio companies reach key value-added milestones. The firm will consider opportunities based in China and North America. Companies with a strong China angle or involvement are their sweet spot.

The firm focuses mostly on therapeutics, and also open to Diagnostics. The firm is currently most interested in small molecule first-in-class drugs. The firm is opportunistic in terms of subsector and indication and is willing to consider companies targeting orphan indications. For therapeutics, the firm is looking to invest in pre-clinical stage. For diagnostics, the firm will consider companies from in-development to clinical stages. The firm will not invest in Medical Devices Healthcare IT companies.

The firm looks to act as a lead investor in seed round investments and can participate as either lead or co-investor in series A investments. The firm is looking for companies with skilled and experienced management teams. The firm prefers to support companies that own exclusive IP protection with renowned universities or research institutions. The firm also prefers to work with companies that have a technical expert and experienced in clinical trials.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

The venture capital arm of a US health system looks to invest between $500K-$5M, in Seed, Series A and Series B rounds. The firm is looking to invest in technologies that can be leveraged by a large healthcare system. The group is currently looking for opportunities throughout the United States.

The girm is looking to invest in companies with strong ROI potential that also are strategically aligned with the group’s parent healthcare system. The firm is interested in companies meeting this criteria operation in the digital health, medical devices and diagnostics. The firm is open to investing in companies that are pre-revenue, including those with a product still in development or in clinical trials. The firm does not invest in therapeutics or Class III medical devices.

The firm is looking for companies with experienced management teams and generally seeks board representation following investment. The group is also interested in forming joint-ventures or co-development programs when relevant and looks to leverage its connection to the health system to aid companies as well.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.